This trial is active, not recruiting.

Condition cataracts
Treatments hoya af-1 iol, revital vision
Phase phase 4
Sponsor Innovative Medical
Start date September 2010
End date December 2011
Trial size 20 participants
Trial identifier NCT01382641, Hoya AF-1


The doctors participating in this study are looking to show improved vision with the HOYA AF-1 aspheric intraocular lens after cataract surgery. They will also study the use of Revital Vision (neuro-sensory testing) in providing the highest potential for improved vision.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
hoya af-1 iol
The patients will be assessed for three months
revital vision
The patients will be assessed for three months.

Primary Outcomes

Measuring Ocular Dominance
time frame: 3 months
Overall post surgical outcomes
time frame: 3 months

Secondary Outcomes

Measuring visual acuities
time frame: 3 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Patients must desire to pursue some type of mono-vision fit, mono-vision lasik, or mono-vision cataract surgery with lens implant. 2. Patients must be candidates for intraocular lens implantation for the correction of aphakia following extracapsular cataract extraction by phaco-emulsification. 3. Patients must be candidates for bilateral implantation and desiring post-operative spectacle independence through targeted mono-vision. 4. Patients must have less than 1.50 diopters of corneal astigmatism 5. Patients must have the potential for best corrected visual acuity of 20/30 or better in each eye. 6. Patients must have the mental capacity to cooperate when undergoing a detailed postoperative refractive examination. 7. Patients must be an adult. 8. Patients must provide written informed consent for cataract surgery. 9. Patients must be willing and able to return for scheduled follow-up examinations for a period of 3 months (post-second eye) post-operatively. 10. Patients must be willing and able to provide feedback to various survey questions regarding overall satisfaction and ease of adaptation to mono-vision and range of vision, etc. Exclusion Criteria: 1. Patients with 1.50 diopters or more of corneal astigmatism 2. Patients requiring a lens power less than 6 D or greater than 30 D 3. Patients with any anterior segment pathology (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, corneal dystrophy or corneal degeneration, tear film deficiency, poor pupil dilation, etc.). 4. Patients with uncontrolled glaucoma or who require current treatment for glaucoma, or with visual field loss as a result of glaucoma. 5. Patients with retinal pathology or a history of retinal detachment. 6. Patients with proliferative diabetic retinopathy, macular degeneration, or other degenerative visual disorders. 7. Patients with a history of previous ocular surgery including corneal refractive surgery. 8. Patients with congenital bilateral cataracts. 9. Patients with marked microphthalmos or aniridia. 10. Patients who have only one functioning eye. 11. Patients who do not have the potential for visual acuity of 20/30 or better in each eye. 12. Patients lacking intact binocular vision. 13. Patients who do not have an intact capsulorhexis and posterior capsular bag at the time of cataract removal and lens implantation. 14. Patients who have incomplete or damaged zonules, or who have zonular rupture during cataract removal. 15. Patients with pupils greater than 7mm

Additional Information

Official title Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery
Trial information was received from ClinicalTrials.gov and was last updated in October 2011.
Information provided to ClinicalTrials.gov by Innovative Medical.